Clinical and radiographic response in three children with recurrent malignant cerebral tumors with high-dose tamoxifen

Pediatric Hematology and Oncology

Volumn 16, Issue 3, 1999, Pages 245-250

  Weyl Ben Arush, M ^a,b   Postovsky, S ^a   Goldsher, D ^b   El Hasid, R ^b   Constantini, S ^c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c Dana Children's Hospital   (Israel)

Author keywords

Angiogenesis; Brain neoplasm; Protein kinase C; Tamoxifen

Indexed keywords

ANTIESTROGEN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ESTROGEN RECEPTOR; ETOPOSIDE; PROTEIN KINASE C; TAMOXIFEN; VINCRISTINE;

ADOLESCENT; ANGIOGENESIS; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHILDHOOD CANCER; CLINICAL FEATURE; EPENDYMOMA; FEMALE; HUMAN; HUMAN TISSUE; MALE; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PROGNOSIS; TUMOR RECURRENCE; TUMOR VOLUME;

ADOLESCENT; BRAIN NEOPLASMS; CHILD, PRESCHOOL; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE C; TAMOXIFEN;

EID: 0345161794     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/088800199277308     Document Type: Article

References (15)

1. Duffner PK, Cohen MR, Meyers MH. Survival of children with brain tumors: SEER program 1973-1980. Neurology. 1986;36:597-601.
2. Pasqualini JR, Sumida C, Giambiagi N. Pharmacodynamic and biological effects of antiestrogens in different models. J Steroid Biochem. 1988;31:613-643.
3. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994;79:185-188.
4. Couldwell WT, Weiss MH, De Giorgio CM, et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high dose tamoxifen. Neurosurgery. 1993;32:485-490.
5. Vertosick FT, Selker RG, Pollack IF, Arena V. The treatment of intracranial malignant gliomas using oral administered tamoxifen therapy: preliminary results in a series of failed patients. Neurosurgery. 1992;30:897-903.
6. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931-10934.
7. Blood CH, Zetter BR. Tumor interactions with vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta. 1990;1032:89-118.
8. Bianco AG, De Placido S, Gallo C. Adjuvant therapy with tamoxifen in operable breast cancer: 10 years results of the naples (GUN) study. Lancet. 1988;2:1095-1099.
9. Wakeling AE, Duke M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867-3873.
10. O'Brian CA, Ward NE, Anderson BW. Role of specific interactions between protein kinase C and triphenylethylenes: a new class of protein kinase inhibitors. J Natl Cancer Inst. 1986;76:1243-1246.
11. Nakadate T, Jeng AY, Blumberg PH. Comparison of protein kinase C functionnal assays to clarify mechanisms of inhibitor action. Biochem Pharmacol. 1988;37:1541-1545.
12. Gagliardi A, Collins DC. Inhibition of angiogenesis by anti-estrogens. Cancer Res. 1993;53:533-535.
13. Kelly RH, Sekler RG, Vertosik FT. Effects of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines. Cancer Res. 1990;50:7134-7138.
14. Baltuch GH, Couldwell WT, Villeneuve JG, Yong VW. Protein kinase C inhibitors suppress cell growth in established and low passage glioma cell lines: a comparison between Staurosporine and tamoxifen. Neurosurgery. 1993;33:495-501.
15. Gastl G, Hermann T, Steurer M, Zmija L, Gunsihuis E, Unger C, Kraft A. Angiogenesis as a target for tumor treatment. Oncology. 1997;54:177-184.